The Goldman Sachs Group Forecasts Strong Price Appreciation for Agilent Technologies (NYSE:A) Stock

Agilent Technologies (NYSE:A) had its price target increased by The Goldman Sachs Group from $155.00 to $175.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s price objective suggests a potential upside of 11.31% from the stock’s current price.

A number of other research analysts have also commented on A. HSBC lowered their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Wall Street Zen raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. Barclays boosted their price objective on shares of Agilent Technologies from $150.00 to $175.00 and gave the stock an “overweight” rating in a research note on Thursday. Robert W. Baird upped their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a report on Tuesday, May 26th. Finally, Morgan Stanley raised their target price on shares of Agilent Technologies from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $170.33.

Agilent Technologies Stock Up 1.4%

Shares of A traded up $2.13 during mid-day trading on Thursday, hitting $157.22. 1,992,931 shares of the company’s stock were exchanged, compared to its average volume of 2,232,849. The stock has a market cap of $44.40 billion, a price-to-earnings ratio of 31.56, a P/E/G ratio of 2.73 and a beta of 1.25. The firm has a fifty day moving average of $139.16 and a two-hundred day moving average of $126.65. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. Agilent Technologies has a twelve month low of $108.35 and a twelve month high of $163.75.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. The business had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. Agilent Technologies’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, sell-side analysts forecast that Agilent Technologies will post 6.05 earnings per share for the current year.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of A. California State Teachers Retirement System raised its stake in Agilent Technologies by 12,343.3% during the 2nd quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after purchasing an additional 54,138,451 shares during the last quarter. Norges Bank acquired a new stake in Agilent Technologies in the 4th quarter worth $549,158,000. Bank of New York Mellon Corp increased its holdings in shares of Agilent Technologies by 87.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock worth $695,227,000 after purchasing an additional 2,440,360 shares during the period. Legal & General Group Plc bought a new position in shares of Agilent Technologies during the 2nd quarter worth about $260,101,000. Finally, AQR Capital Management LLC raised its position in shares of Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after buying an additional 1,652,244 shares during the last quarter. Institutional investors own 87.41% of the company’s stock.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.